Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
542 questions in 42 reviews · Skin
current versionsNo studies 542 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ustekinumab vs placebo Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Ease of compliance to an intervention or a treatment ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Ustekinumab vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Guselkumab vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Guselkumab vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Guselkumab vs placebo Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Guselkumab vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Secukinumab vs placebo Proportion of participants cleared or almost clear ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Secukinumab vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Secukinumab vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Secukinumab vs placebo Proportion of participants with adverse effects in the short term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Secukinumab vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Tavaborole 5% solution vs vehicle Clinical Cure ‐ not measured · People with fungal infections of the toenails Topical and device‐based treatments for fungal infections of the toenails (2020) · Cochrane | no estimate extracted | NR | No studies |
P‐3051 (ciclopirox 8% hydrolacquer) vs comparators Clinical cure ‐ not measured · People with fungal infections of the toenails Topical and device‐based treatments for fungal infections of the toenails (2020) · Cochrane | no estimate extracted | NR | No studies |
1064‐nm Nd:YAG laser vs no treatment or sham treatment Complete cure ‐ not measured · People with fungal infections of the toenails Topical and device‐based treatments for fungal infections of the toenails (2020) · Cochrane | no estimate extracted | NR | No studies |
1064‐nm Nd:YAG laser vs no treatment or sham treatment Clinical cure ‐ not measured · People with fungal infections of the toenails Topical and device‐based treatments for fungal infections of the toenails (2020) · Cochrane | no estimate extracted | NR | No studies |
Luliconazole 5% solution vs vehicle Clinical Cure ‐ not measured · People with fungal infections of the toenails Topical and device‐based treatments for fungal infections of the toenails (2020) · Cochrane | no estimate extracted | NR | No studies |
Ciclopirox 8% lacquer vs vehicle Clinical cure ‐ not measured · people with fungal infections of the toenails Topical and device‐based treatments for fungal infections of the toenails (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 1 mg vs placebo Depression · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 1 mg vs placebo Patient satisfaction · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 0.25 mg vs placebo Depression · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 0.25 mg vs placebo Patient satisfaction · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 5 mg vs placebo Depression · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Serlopitant 5 mg vs placebo Patient satisfaction · chronic pruritus of unknown origin Interventions for chronic pruritus of unknown origin (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Placebo · patients with moderate to severe eczema Systemic treatments for eczema: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Bleach bath vs placebo or bath emollient No of participants in whom S. aureus was isolated · children and adults with atopic dermatitis Interventions to reduce Staphylococcus aureus in the management of eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week Secondary: investigator‐rated reduction in severity Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks… Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Irradiation with UV light: local narrow‐band UVB vs local PUVA Primary: participant‐rated good/excellent control of symptoms Not measured · people with hand eczema unresponsive to clobetasol propionate Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Topical calcineurin inhibitors: tacrolimus 0.1% ointment vs mometasone furoate ointment Primary: investigator‐rated good/excellent control of symptoms ‐ Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Topical calcineurin inhibitors: tacrolimus 0.1% ointment vs mometasone furoate ointment Primary: participant‐rated good/excellent control of symptoms ‐ Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Topical calcineurin inhibitors: tacrolimus 0.1% ointment vs vehicle Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand… Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Topical calcineurin inhibitors: tacrolimus 0.1% ointment vs vehicle Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand… Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Oral retinoids: alitretinoin 30 mg vs placebo Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week Primary: participant‐rated good/excellent control of symptoms Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks… Interventions for hand eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Narrowband UVB phototherapy vs medium‐dose UVA‐1 phototherapy (50 J/cm²) Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | NR | No studies |
Narrowband UVB phototherapy vs low‐dose UVA‐1 phototherapy (20 J/cm²) Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | NR | No studies |
Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²) Secondary outcome: Improvement of disease damage ‒ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head… Interventions for morphea (2019) · Cochrane | no estimate extracted | NR | No studies |
Clarithromycin vs placebo The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs placebo or vitamins The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir vs placebo, vitamins, or no treatment The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir vs placebo, vitamins, or no treatment Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |